OnaWave Medical’s Post

Come visit the New Technology Show and let's chat about how IKA can help you with anything from pipetting up to automated cell or algae growth in a bioreactor! Let's connect if you have specific lab equipment needs! #LABioTechWeek

The need of building ecosystem to elevate the #growth of innovating startup’s as solution for overcoming barriers was strongly underlined in today’s discussion I had pleasure to take part in. Panel session during HealthTech City meeting led by Nikoletta Magdalena Buczek from Mother and Child Startup Challenge & NABIO Medical Technologies consisted of representatives from different fields: ➡️ Joanna Broy - EIT Health ➡️ Tomasz Rudolf - Doctor.One ➡️ Krzysztof Medrala - MedApp S.A. 🤝We all agreed that communication between multiple stakeholders is the way to overcome hurdles that entrepreneurs encounter. 💡These conclusions are only strengthening the importance of actions taken by Związek BioForum as #networking is one of the most important aspects of its approach. That is how we can create community and represent it’s voice to governmental authorities ❗️ If you want to join this community: ✅ follow Central European BioForum ✅ SAVE THE DATE💥 2-3 April 2025 and be with us at biggest #biotech #business meeting in Warsaw 👉 #CEBioForum2025 Partners of today’s meeting:EIT Health , Mother and Child Startup Challenge , Central European BioForum , CampusAI Poland , MamStartup , My Company Polska , Cup of Me

⚕️ The 2023 Europe Health Tech 200 is HolonIQ’s annual list of the most promising startups from across digital health, biotech, medtech and other areas where entrepreneurs are driving healthcare innovation. UK, Germany and France are the European health tech superpowers with over two thirds of the market. As market conditions have tightened - both globally and across Europe - the 2023 cohort reflects an older selection of more established business models that are demonstrating traction in the market. Learn more 👉

“#Medtech is an industry that relies on collaboration between research and industry to identify and solve challenges, and develop devices to improve health outcomes. This is an area #SouthAustralia excels in.” ⚕️👩💻 Why? A strong research base; with SA-based Cooperative Research Centres (CRCs), all three universities, and SA startups investing in medtech-related R&D and bringing their innovations to market. 💡 Read more about SA medtech in this summary from DSD’s Dr Louise Smith: 👉 https://ow.ly/UVN050SBZ9k 📸 Dr Louise Smith, Department of State Development

🌍 𝑯𝒐𝒘 𝒂𝒓𝒆 𝒊𝒏𝒕𝒆𝒓𝒏𝒂𝒕𝒊𝒐𝒏𝒂𝒍 𝒄𝒐𝒍𝒍𝒂𝒃𝒐𝒓𝒂𝒕𝒊𝒐𝒏𝒔 𝒔𝒉𝒂𝒑𝒊𝒏𝒈 𝒕𝒉𝒆 𝒇𝒖𝒕𝒖𝒓𝒆 𝒐𝒇 𝑯𝒆𝒂𝒍𝒕𝒉𝑻𝒆𝒄𝒉? Reflections from the Trinational HealthTech Days 2023 in Strasbourg. Last week, our CEO Saribek Karapetyan participated in a significant event for the #HealthTech sector, uniting France, Switzerland, and Germany. 🤝 𝐓𝐫𝐚𝐧𝐬𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐒𝐲𝐧𝐞𝐫𝐠𝐲 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐓𝐞𝐜𝐡: The Trinational HealthTech Days, driven by key players like BadenCampus, Innovation Office University of Basel , Quest for change, and the Life Science Accelerator Baden-Württemberg, showcased the necessity of international collaboration for healthcare innovation and market expansion. 🔍 This event also highlighted the Baden region’s significant health sector, employing 65,000 people and hosting major institutions like the Fraunhofer Institutes. As Malaika Lauk of BadenCampus puts it, “𝘛𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘪𝘯 𝘰𝘶𝘳 𝘉𝘢𝘥𝘦𝘯 𝘳𝘦𝘨𝘪𝘰𝘯 𝘪𝘴 𝘦𝘯𝘰𝘳𝘮𝘰𝘶𝘴. 𝘞𝘦 𝘢𝘪𝘮 𝘵𝘰 𝘦𝘭𝘦𝘷𝘢𝘵𝘦 𝘰𝘶𝘳 𝘷𝘪𝘴𝘪𝘣𝘪𝘭𝘪𝘵𝘺 𝘢𝘴 𝘢 𝘏𝘦𝘢𝘭𝘵𝘩 𝘙𝘦𝘨𝘪𝘰𝘯 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘵𝘩𝘦𝘴𝘦 𝘵𝘳𝘪𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱𝘴.” 🔗 A key forum for startups such as Visual Abstract, the event facilitated connections with investors and major industry players like Pfizer. Thorsten Mintel, Director of Strategic Innovation at Pfizer, noted the importance of startup collaboration in enhancing patient care and driving innovation in production and logistics. Saribek Karapetyan shared, “𝘈𝘵 𝘝𝘪𝘴𝘶𝘢𝘭 𝘈𝘣𝘴𝘵𝘳𝘢𝘤𝘵, 𝘸𝘦 𝘢𝘳𝘦 𝘥𝘦𝘥𝘪𝘤𝘢𝘵𝘦𝘥 𝘵𝘰 𝘥𝘦𝘮𝘺𝘴𝘵𝘪𝘧𝘺𝘪𝘯𝘨 𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘧𝘰𝘳 𝘦𝘷𝘦𝘳𝘺𝘰𝘯𝘦. 𝘖𝘶𝘳 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮 𝘰𝘧𝘧𝘦𝘳𝘴 𝘵𝘩𝘦 𝘱𝘩𝘢𝘳𝘮𝘢𝘤𝘦𝘶𝘵𝘪𝘤𝘢𝘭 𝘢𝘯𝘥 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 𝘢𝘯 𝘢𝘷𝘦𝘯𝘶𝘦 𝘵𝘰 𝘦𝘢𝘴𝘪𝘭𝘺 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘦 𝘢𝘯𝘥 𝘯𝘢𝘷𝘪𝘨𝘢𝘵𝘦 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘧𝘪𝘤 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩, 𝘴𝘩𝘢𝘱𝘪𝘯𝘨 𝘵𝘩𝘦 𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦.” 💡 𝑾𝒆 𝒊𝒏𝒗𝒊𝒕𝒆 𝒐𝒖𝒓 𝒏𝒆𝒕𝒘𝒐𝒓𝒌: What are your thoughts on the role of international collaborations in HealthTech? How do you see such events influencing the sector’s trajectory? #TrinationalHealthTechDays #HealthTechInnovation #VisualAbstract #HealthcareCollaboration https://lnkd.in/euJiswT8.

🔍 What does it take to successfully scale in #HealthTech to Series B & beyond? In the HealthTech Breakfast Club February's edition the conversation delved deeper into the process of scaling beyond Series B funding, including the cohesion of leadership teams and strategic considerations regarding organic vs. inorganic growth. From looking at growth metrics to M&A target assessment when thinking about multiples, valuation and future integration both of tech and people. This month's panel was made up of: 🔹Dr. Ben Maruthappu - CEO of Cera 🔹Mong-Trang Sarrazin - CFO of Unmind 🔹Ian Coyne - Partner at Coulter Partners 🔹Michael Treskow - Partner at Eight Roads Key takeaways from the session: 🏷 Flexibility in leadership is crucial, both in response to overarching trends and when confronted with growth hurdles during the business's expansion. 📜 Domain expertise proves vital even in the early stages, enabling informed decision-making for both organic and strategic growth initiatives. This expertise also fosters credibility with investors, whether equity or debt stakeholders. 📦 Understanding unit economics is imperative for scaling operations. A meticulous focus on metrics like Customer Acquisition Cost (CAC) to Customer Lifetime Value (CLTV) for organic growth, as well as having a deep comprehension of the financial dynamics behind potential acquisitions. 🔒 M&A serve as vehicles for market expansion or product diversification. Recognizing the underlying purpose is pivotal to anticipate and address integration challenges, whether they pertain to technology infrastructure, personnel dynamics, or cultural alignment. Identifying and mitigating risks associated with execution is paramount. 🗝 Founders venturing into the healthtech sector face a distinctive risk profile. While they may exhibit a greater willingness to challenge conventional norms compared to counterparts in other industries, prioritize assembling a capable leadership team early on is key to realize their ambitious vision. Special thanks to Eight Roads for hosting this month's session at their offices and supporting this event. With Molly Gilmartin, Investment Manager AlbionVC An exciting new #TechBio chapter is coming up in March with Leigh Brody, click here to learn more: https://lnkd.in/eiPk7mGf #community #vc #founders #operators #experts #investors #venturecapital #healthcare #techbio #growth #seriesB #digitalhealth #leadershipteam #scaling

The LifeSciences@Work Venture Challenge Fall 2023 winner will be announce in the closing programme of the Dutch Life Sciences conference on December 7. Startup companies and young companies form the seeds and the future of the Dutch life sciences landscape. The LifeSciences@Work Venture Challenge helps researchers in the life sciences to turn their research into a viable product or service that helps patients, physicians or other researchers. It is a 10-week programme to develop an initial idea – a breakthrough research result – into a solid business case. The participants of the Venture Challenge Fall 2023 edition get the honour to pitch their invention at the DLSC. We understand that it is very hard to wait to get to know the teams! Therefore, we’re giving you a sneak peek:  https://lnkd.in/e2MAGqn5 Register now for the final tickets of the Dutch Life Sciences Conference on 7 December 2023, in Leiden >>https://lnkd.in/gDRMcDA The Dutch Life Sciences Conference is powered by Health~Holland.

What comes to your mind when you hear the name ODIN? If it’s an old guy with birds on his shoulders, here’s a new one for you: ODIN is The Open Discovery Innovation Network. A patent-free drug discovery and diagnostics platform funded by the Novo Nordisk Foundation. The scientific scope of the programme is cardiovascular diseases, cardiometabolic diseases and infectious diseases. ODIN bridges the gap between academia and industry, facilitating open, precompetitive research collaborations. The initiative is rooted at Aarhus University, but five Danish universities are partners, and the collaboration opportunities extend to international participants, creating a global network of innovation 🌍 💡 One unique aspect of ODIN is that all funded projects share their knowledge with the public, allowing for free commercial use. This open approach eliminates the need for IP negotiations, making it easier and faster to initiate projects. 🤝 As a company, you can join ODIN at no cost and are not required to make cash contributions. While active participation is encouraged, there are no fixed levels of contributions or time registration required. This flexible model is designed to foster collaboration without barriers. Do it for the easy of collaboration, scouting of new technology and talent, access to new resources and to de-risk wild ideas. 🎉 ODIN also offers a series of matchmaking and ideation events. These events provide a platform to showcase research needs and project ideas, find partners, and receive valuable input from the ODIN community. Their digital matchmaking platform is open, making it easy to connect and collaborate. And you can pitch either an idea, method or product. Read all about it right here: https://lnkd.in/dYzSzz4H

What unique challenges do early stage companies face when they’re focusing on bioconvergence technologies? In this clip, Assaf Barnea, CEO of Sanara Ventures, emphasizes that this convergence is not just about blending novel technologies but also about uniting diverse experts from various fields. While this integration poses challenges, it’s an essential hurdle to overcome. The synergy between different people and technologies brings disruptive innovations to the space. Our latest #LSIUSA24 panel, ‘Bioconvergence: Breaking Down Silos in Disruptive Innovation’, defines the "bioconvergence" happening in healthcare, explores fresh opportunities in this segment, and highlights what it means for the future of the industry. Hear from: • Marc Alcser (Moderator) — Stradling Yocca Carlson & Rauth LLP • Assaf Barnea — Sanara Ventures • Ariane Tom, PhD — Kaleida Capital • Suraj Mudichintala — Action Potential Venture Capital 🔗 Watch full panel here: https://lnkd.in/ddy4F_x8 Want to see more content like this? Registration and applications to present are open for LSI Europe ‘24 this September 16th - 20th at the Penha Longa Resort, in Portugal. Secure your spot today to ensure you get the best rate and secure a hotel room onsite.

The time has come for the first Bi-weekly update from the Aniverse in 2024! The last two weeks were permeated with secretive happenings, so I will summarize it without disclosing the details (those will go out in the following few weeks): 1) VC Investment Four years after starting a company, during the most brutal fundraising environment ever, after investments from EIT Climate-KIC RIS and 70 angel investors, we realized our first VC investment. More about our lucky partners soon! (joke, the luck is mutual) 2) New HQ We signed the contract for the new, 3x bigger HQ that will unify offices, production, lab, fulfillment, and warehouse. We are moving in this month and will share more soon! 3) Clinical study - results We received the raw data from the participants of our first clinical trial. Our bioinformaticians interpreted the results, and I could just say that they are better than expected, confirming the power of bioactive compounds for gut health. These are only the first 28 samples (the study altogether has 150 ppl through 3 arms) - the official results are coming out soon! 4) Scientific Advisory Board We formed our Scientific Advisory Board of four extraordinary international scientists. We will onboard two more in the following two weeks and disclose all of them at once. 5) New team members We have three more scientists in our core team. I'll share each in the following posts (starting with this one). The following two weeks are reserved for the magic of shaping the future: - Marta, Manuela, Iva, and I will be presenting Ani Biome at CES in Las Vegas (Dragan & Bojan, thanks for this opportunity one more time; see you soon!), after which we will go together to our US HQ in SF - Nika will be presenting Ani on a few longevity panels at the World Economic Forum in Davos Looking forward to everything 2024 will bring! 🦄 💫 👅 #longevity #biotech #startup #venturecapital #investment #machinelearning #scienceandtechnology #mentalhealth #guthealth